Mink Therapeutics Investor Relations Material
Latest events
Q2 2025
Mink Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mink Therapeutics Inc
Access all reports
Mink Therapeutics Inc. is a biotechnology company that focuses on developing immunotherapy treatments. The company specializes in creating allogeneic, off-the-shelf therapies derived from invariant natural killer T (iNKT) cells. These therapies are designed to target cancer and other immune-related diseases. Mink Therapeutics’ approach aims to harness the natural immune response, offering potential treatments that enhance the body’s ability to fight diseases. The company is headquartered in New York, United States, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
INKT
Country
🇺🇸 United States